TECHNOLOGY PLATFORMS Archives

PD-1 Blockade with a DLL3 TCE Potentiates Efficacy in SCLC

Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...

Unveiling Mechanisms of MRTX1133 Resistance

Recent years have seen major advances in KRAS G12D-targeted therapeutics. However, acquired drug resistance remains a significant clinical challenge, with...

Development of the Venetoclax-Resistant AML Model

Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...

Biophysical Methods for Rapid Screening and Hit Validation

At DDC 2026, WuXi AppTec presented a poster showcasing our integrated discovery platform designed to accelerate the identification and validation...

Spectral Shift for Ultra-High-Throughput Binding Assays

High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...

DEL and Display Technologies Empower Discovery of Peptide Drugs

In recent years, peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages,...

D2B: Direct-to-Biology Platform

Looking for a solution to accelerate your drug discovery processes? WuXi AppTec’s integrated Direct-to-Biology (D2B) platform is a cost-effective and...

Efficacy of Biologics in Humanized Mouse Models for IBD

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...

CTHRC1 as a Novel Candidate for Neurodevelopmental Disorders

Cognitive dysfunction affects over 50 million individuals worldwide, with Alzheimer’s disease (AD) representing two-thirds of cases. Due to the complexity...

Knowledge Library